on AMOEBA (EPA:ALMIB)
Amoéba Engages Shareholders in New Fundraising Round
Amoéba has announced a €10 million capital increase involving share subscription warrants. This move aims to sustain its commercial biocontrol launch and support future cosmetics platform monetisation. Expected from 2027, this monetisation should ensure long-term financing, shifting reliance from market fundraising to sales-driven revenue, with Amoéba targeting self-sufficiency by 2029.
The initiative offers shareholders pre-emptive rights and free warrants, enhancing potential future gains. Benoit Villers, Chairman, highlights shareholder integration in addressing funding strategies. Jean-François Doucet, CEO, notes advancements including biofungicide market entry and a new distribution deal with Syngenta by 2028. In cosmetics, Amoéba aims for a 2027 agreement, boosting the platform's value.
Despite challenges, Amoéba remains committed to rewarding shareholder investment. The upcoming capital increase seeks to refine Amoéba's equity positions and drive substantial growth, forecasting €80 million in revenue by 2032.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news